Berritt, Simon

An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

Owen, D. R., Allerton, C. M. N., Anderson, A. S., Aschenbrenner, L., Avery, M., Berritt, S., Boras, B., Cardin, R. D., Carlo, A., Coffman, K. J., et al. (2021) · Science

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 2,033

Targeting MRTF/SRF in CAP2‐dependent dilated cardiomyopathy delays disease onset

Xiong, Y., Bedi, K., Berritt, S., Attipoe, B. K., Brooks, T. G., Wang, K., Margulies, K. B., & Field, J. (2019) · JCI Insight

Cardiomyopathy and Myosin StudiesCardiac electrophysiology and arrhythmias

Cited by 20